Here, we present a case of metastatic pancreatic adenocarcinoma harboring a germline BRCA1 mutation and a high tumor mutation burden (TMB)....Ongoing therapy with olaparib and pembrolizumab has been well tolerated, and he remains clinically well with an excellent PS. Imaging 6 months after the addition of olaparib (16 months after his initial diagnosis) has revealed a complete radiologic response to therapy, with no evidence of residual active malignancy on positron emission tomography or computed tomography or magnetic resonance imaging (Figs 2C and 2D)...this case report describes a profound clinical response to sequential platinum-based chemotherapy, pembrolizumab, and olaparib in a patient with advanced PC harboring a germline BRCA1 mutation and high TMB.